Protein C News and Research

RSS

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.

3 Jan 2022

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

31 Dec 2021

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

New study shows how cells eat the things around them

A new study shows how cell membranes curve to create the "mouths" that allow the cells to consume things that surround them.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

30 Dec 2021

The use of monoclonal antibodies against infectious pathogens

Joshua Tan of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health wrote a review article in the journal DNA and Cell Biology about the role of monoclonal antibodies and briefly described a study on bispecific antibodies that neutralize SARS-CoV-2.

30 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

In a new study, findings suggest that in some cases, tracking the distribution and frequency of SARS-CoV-2 minor variant genomes at a population level would help in predicting the emergence of a new dominant viral genome sequence.

30 Dec 2021

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

A new study, focused on the SARS-CoV-2 Omicron variant, presented a modeling result from an analysis of genome surveillance data in Gauteng province, South Africa, using an existing estimation technique.

30 Dec 2021

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

Omicron will outcompete Delta variant for next 4-5 months globally: Genome study

A new study published in the pre-print server medRxiv* hypothesized that the emergence of more immune invasive or transmissible variants of SARS-CoV-2 was associated with increased genetic distinctiveness from the original or previous strains.

29 Dec 2021

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs).

29 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

Protein C News and Research

Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

SARS-CoV-2 omicron variant may be less severe than the delta variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

New study shows how cells eat the things around them

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

The use of monoclonal antibodies against infectious pathogens

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

P323L mutations in SARS-CoV-2 are highly predictive of the emergence of new variants

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

An integrated computational methodology for COVID drug prioritization

Omicron will outcompete Delta variant for next 4-5 months globally: Genome study

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Omicron analysis shows no clear evidence for increased virulence or lethality

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News